RNUG.F Stock Overview
Researches, develops, and commercializes cell-based therapies in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ReNeuron Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0011 |
| 52 Week High | UK£0.051 |
| 52 Week Low | UK£0.0007 |
| Beta | 0.83 |
| 11 Month Change | 0% |
| 3 Month Change | -62.07% |
| 1 Year Change | n/a |
| 33 Year Change | -99.92% |
| 5 Year Change | -99.96% |
| Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| RNUG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | n/a | 16.1% | 31.6% |
Return vs Industry: Insufficient data to determine how RNUG.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RNUG.F performed against the US Market.
Price Volatility
| RNUG.F volatility | |
|---|---|
| RNUG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNUG.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RNUG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 26 | n/a | www.reneuron.com |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.
ReNeuron Group plc Fundamentals Summary
| RNUG.F fundamental statistics | |
|---|---|
| Market cap | US$2.54m |
| Earnings (TTM) | -US$5.07m |
| Revenue (TTM) | US$249.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs RNUG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNUG.F income statement (TTM) | |
|---|---|
| Revenue | UK£249.00k |
| Cost of Revenue | UK£3.65m |
| Gross Profit | -UK£3.40m |
| Other Expenses | UK£1.67m |
| Earnings | -UK£5.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.089 |
| Gross Margin | -1,367.47% |
| Net Profit Margin | -2,037.35% |
| Debt/Equity Ratio | 0% |
How did RNUG.F perform over the long term?
See historical performance and comparison